Minnesota Department of Health says 129 clinics in Minnesota got drug supplies from a pharmaceutical distributor that has been at the center of national concern about noninfectious meningitis cases. "It is not known at this time how many patients in Minnesota are affected," the state agency said in a Tuesday afternoon alert…Mayo Clinic spokesman Bryan Anderson said no Mayo sites "purchased any of the products (methylprednisolone, triamcinolone acetate injection, and cardioplegia solution) from New England Compounding Center that were specifically mentioned in FDA alerts." He noted, though, that "some Mayo Clinic sites have purchased a limited number of other products from NECC, but all of these products were removed from the shelves on Oct. 5."
Post-Bulletin by Jeff Hansel
Tags: Bryan Anderson, Industry News & Competitive Intelligence, Mayo Clinic Proceedings, Mayo Clinic Rochester, Minnesota Department of Health, New England Compounding Center, noninfectious meningitis, Pharmacology, Post Bulletin, tainted drugs